Table 1.
Patient demographics and baseline laboratory values
| Characteristic | Cinacalcet group (n = 33) | Control group (n = 33) | P-value |
|---|---|---|---|
| Sex, n (%) |
|
|
0.324 |
| Male |
20 (60.6) |
15 (45.5) |
|
| Female |
13 (39.4) |
18 (54.5) |
|
| Age, years |
|
|
0.520 |
| mean (SD) |
48.8 (11.5) |
47.2 (8.4) |
|
| Range |
25 to 71 |
28 to 64 |
|
| Duration of dialysis, months mean (SD) |
78.7 (39.8) |
71.3 (40.6) |
0.454 |
| Medical history, n (%) |
|
|
|
| hypertension |
32 (97.0) |
29 (87.9) |
0.355 |
| diabetes mellitus |
7 (21.2) |
5 (15.2) |
0.751 |
| peripheral vascular disease |
2 (6.1) |
0 (0.0) |
0.492 |
| cerebrovascular disease |
2 (6.1) |
0 (0.0) |
0.492 |
| congestive heart failure |
1 (3.0) |
0 (0.0) |
1.000 |
| iPTH, median (Q1,Q3) (pg/ml)* |
729 (518, 1424) |
649 (490, 1143) |
0.783 |
| Serum calcium, mean (SD) (mg/dL)* |
9.8 (0.6) |
9.6 (0.8) |
0.273 |
| Serum phosphorus, mean (SD) (mg/dL)* |
5.8 (1.7) |
5.3 (1.4) |
0.231 |
| Ca X P, mean (SD) (mg2/dL2)* |
53.8 (16.3) |
48.7 (14.5) |
0.189 |
| Serum FGF23 (Q1,Q3) (RU/ml)* |
3960 (2430, 6609) |
2085 (741, 7182) |
0.134 |
| Renal Kt/V (Q1, Q3) |
0.0 (0.0, 0.1) |
0.0 (0.0, 0.5) |
0.170 |
| Peritoneal Kt/V (SD) |
1.8 (0.5) |
1.8 (0.6) |
0.956 |
| Total Kt/V (SD) | 1.9 (0.4) | 2.1(0.6) | 0.124 |
*Post-washout (week 0) value.
Q1 first quartile, Q3 third quartile.